DRAQ7™ fluoresces in the far-red – with the same spectral properties that have made DRAQ5™ a reagent of choice in HCS. DRAQ7™ only labels membrane-compromised dead, dying and apoptotic cells and g...read more
Organization: Memorial Sloan-Kettering Cancer Center Read more »
5 out of 5EASE OF USE
5 out of 5AFTER SALES SERVICE
4 out of 5VALUE FOR MONEY
Review date: 31 Dec 2012
Application Area: Live cell screening DRAQ7™ Novel Cell-Impermeant DNA Dye
"Draq7 is a great dye for labelling cells and is very easy to use. Using this dye we have been able to do live cell screening of cells, as it is non-toxic to cells. However, overall the cost is a bit expensive for screening."
DRAQ7™ fluoresces in the far-red – with the same spectral properties that have made DRAQ5™ a reagent of choice in HCS.
DRAQ7™ only labels membrane-compromised dead, dying and apoptotic cells and gives clear discrimination between these and healthy cells in high content cytotoxicity and viability assays and in flow cytometry.
The far-red emission, longer wavelength than TOTO-3, permits better combination with other fluorescent probes. It is spectrally compatible with the commonly used orange/red mitochondrial health probes, and UV-excited vital dyes.
DRAQ7™ can be used in RNAi knock-down and long-term, dynamic viability assays to report in vitro cytotoxicity and apoptosis.
Also, DRAQ7™ efficiently counterstains fixed cell and tissue preparations. It offers the same differential nucl:cyto staining for dual compartment segmentation in translocation tracking and cell morphometrics for in vitro toxicology, that has made DRAQ5™ a favourite of HCS assay developers.
DRAQ7™ is supplied as a convenient aqueous, ready-to-use solution. The 1 ml pack size (GBP 140.00 / ca. USD 220.00) is sufficient for at least 200 flow cytometry tests, 300-600 slides and up to 10,000 1536-MTP wells.
Write a review
Sharing your experience will help scientists like you. Achieve Reviewer Status and Win an iPad air (All reviews published will be entered into the next drawing on March 30th 2014).